FDA approves Novo Nordisk's semaglutide as obesity treatment

The US FDA has given the thumbs-up to Novo Nordisk's semaglutide as an injection-based treatment for obesity. This paves the way for massive sales for the Danish pharmaceutical company.

Photo: Novo Nordisk / PR

There is an air of celebration at Novo Nordisk's headquarters, as the US Food and Drug Administration (FDA) has just approved the pharmaceutical company’s application for the use of semaglutide as a treatment for obesity marketed as Wegovy.

This approval will help Novo Nordisk penetrate the lucrative obesity market, where the company has struggled for quite some time.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs